Palantir shares rise 5% premarket as AI-fueled demand powers annual guidance raise
In a remarkable display of market confidence, NAGE stock has surged to a 52-week high, reaching a price level of $11.17 USD. This peak reflects a significant milestone for the company, which now commands a market capitalization of $882 million. According to InvestingPro analysis, the stock appears overvalued at current levels, with the RSI suggesting overbought territory. The company maintains strong fundamentals with a healthy 62.5% gross profit margin and impressive revenue growth of ~30% over the last twelve months. Over the past year, Chromadex Corp (NASDAQ:NAGE), the entity behind NAGE, has witnessed an impressive 292% change in its stock value, indicating a robust turnaround and a bullish trend that has caught the attention of market watchers and investors alike. The company’s strategic initiatives and potential growth prospects appear to be key drivers behind this upward trajectory, with analyst targets ranging from $9.60 to $15.00 per share. InvestingPro rates the company’s overall financial health as "GREAT," with 18 additional premium tips available for subscribers seeking deeper insights into this rapidly growing stock.
In other recent news, Niagen Bioscience Inc. reported a robust financial performance for the first quarter of 2025, with total net sales reaching $30.5 million, a 38% increase compared to the same period last year. The company also achieved a net income of $5.1 million, reversing a net loss of $500,000 from Q1 2024. This performance was driven by strong growth in both e-commerce sales and the Niagen ingredient business, which saw a 31% and 95% year-over-year increase, respectively. Analysts had forecasted revenue of $27.07 million, but the company exceeded these expectations, reflecting strong demand for its products. Additionally, Niagen Bioscience raised its full-year top-line growth outlook to 20-25%, indicating confidence in continued expansion. In the analyst community, firms like H.C. Wainwright have shown interest in the company’s strategic initiatives, particularly the adoption of the NIAGEN IV product. The company is also developing an at-home injectable version expected to launch in Q4 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.